Biotech drug developer Xencor Inc. said Monday that it has licensed some of its technology that boosts the effectiveness of antibody treatments to a Johnson and Johnson company.

The private Monrovia company, which is developing its own protein and antibody therapies, said it signed a multi-year agreement with Centocor Research & Development Inc. of Malvern, Pa. to use Xencor’s XmAb and Xtend technology platforms. The technologies can make certain injectible drugs more convenient for patients because they last longer.

The deal will give Centocor Research access to the platforms, and the right to develop and commercialize products from the technology, in exchange for license fees, milestone payments, and royalties on products commercialized from the collaboration. Financial terms were not announced.

“We look forward to expanding this relationship and enhancing the commercial potential of our platform through partnerships that complement our internal pipeline,” said Chief Executive Bassil Dahiyat in a statement.

This is the fourth licensing agreement that Xencor has signed this year. The company is using the licensing revenue to develop its own drugs for conditions such as inflammatory disease and Hodgkin’s disease.